Iguratimod
Drug profile
Also known as: careram, kolbet, T-614
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Iguratimod is a drug catalogued in DrugCentral. It was first approved by the PMDA in 2012. DrugCentral lists 1 molecular target, including MIF. Recorded indications include Rheumatoid arthritis.
- Molecular targets: MIF (1 listed in DrugCentral).
- Indications: Rheumatoid arthritis.
- Molecular formula: C17H14N2O6S; molecular weight 374.37 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Rheumatoid arthritis
Mechanism & targets
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Macrophage migration inhibitory factor | MIF | unknown | IC50 5.17 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2012-06-29 | PMDA | — | — |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Pneumocystis jirovecii pneumonia | 225.5 |
| Interstitial lung disease | 203.5 |
| Lymphoproliferative disorder | 171.2 |
| Pneumonia bacterial | 92.7 |
| Adult T-cell lymphoma/leukaemia | 60.6 |
| Herpes zoster | 58.4 |
| Varicella zoster pneumonia | 49.6 |
| Osteonecrosis of jaw | 47.6 |
| Diffuse large B-cell lymphoma | 44.7 |
| Atypical mycobacterial infection | 37.9 |
| Listeriosis | 37.8 |
| Lymphoma | 34.7 |
Chemical structure
| Molecular formula | C17H14N2O6S |
|---|---|
| Molecular weight | 374.37 g/mol |
| CAS number | 123663-49-0 |
| InChIKey | ANMATWQYLIFGOK-UHFFFAOYSA-N |
| PubChem CID | 124246 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Iguratimod used for?
DrugCentral lists the following indications for Iguratimod: Rheumatoid arthritis.
How does Iguratimod work?
Its molecular targets in DrugCentral include MIF.
When was Iguratimod first approved?
Iguratimod was first approved by the PMDA in 2012.
What is the chemical formula of Iguratimod?
Iguratimod has the molecular formula C17H14N2O6S and a molecular weight of 374.37 g/mol.
Browse: all drugs starting with I · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4894 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2107455 — compound record and bioactivity
- PubChem CID 124246 — chemical identifiers
- DrugBank DB12233 — drug record
- FDA UNII 4IHY34Y2NV — substance identity
- UniProt P14174 (MIF) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.